Recent studies have associated rosiglitazone, a thiazolidinedione drug, with adverse cardiovascular outcomes in the general population with diabetes. 最近关于罗格列酮(一种噻唑烷二酮(TZD)类药物)的研究显示该药对一般糖尿病患者心血管有不利影响产生。
Although it may be tempting to move away from prescribing thiazolidinedione altogether, they write, long term follow-up data for newer products are not yet available. 尽管完全摆脱处方噻唑烷二酮(TZD)类药物是很有诱惑力的,但是新产品的长期后续的数据尚未公布。
Rosiglitazone is a thiazolidinedione and anti-diabetic drug which control blood sugar effectively through increasing sensitivity of insulin. 罗格列酮(Rosiglitazone)属噻唑烷二酮(TZD)类抗糖尿病药,通过提高胰岛素的敏感性而有效地控制血糖。
Thiazolidinedione(TZD) can affect the secretion function of preadipocyte by regulating the state of cell growth. 吡格列酮可通过调节前脂肪细胞的生长而影响其分泌功能。
Recently, with the increased understanding of the precise mechanisms of TZD, thiazolidinedione class of insulin sensitizer, PPAR γ has also been identified as the major functional receptor for the drugs. In the study of the relationship between PPAR and insulin resistance, considerable gaps appeared. 近年来随着对胰岛素增敏剂噻唑烷二酮(TZD)(TZD)类药物作用机制的深入研究,发现PPARγ是该类药物的主要功能受体,于是展开了对于PPAR与胰岛素抵抗之间关系的研究。